Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic stem cell transplantation.

A Bosi1, B Bartolozzi, S Guidi

  • 1BMT Unit, Department of Hematology, University of Florence, Florence, Italy.

Transplantation Proceedings
|September 27, 2005
PubMed
Summary

Allogeneic stem cell transplantation (HSCT) is now a curative treatment, with evolving donor sources and reduced-intensity conditioning. Despite challenges like transplant-related mortality, HSCT offers a >50% cure rate for early-stage diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strategies for discriminating medulloblastoma ex-vivo through Raman-active CH vibrational modes.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026
Same author

Transgenerational phenotypic plasticity of the two-spotted spider mite (Tetranychus urticae Koch) in response to abamectin.

Experimental & applied acarology·2025
Same author

'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Bone marrow transplantation·2017
Same author

Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT.

Journal of internal medicine·2017
Same author

Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

Leukemia·2017
Same author

Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Bone marrow transplantation·2017

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Allogeneic stem cell transplantation (HSCT) has evolved from an experimental therapy to a curative treatment for various hematologic malignancies and nonmalignant diseases.
  • Indications for HSCT have expanded beyond leukemia and lymphoproliferative disorders to include myelodysplasia, thalassemia, aplastic anemia, and even solid tumors.
  • Significant advancements include a shift towards peripheral blood stem cells, increased use of alternative donors (unrelated, haploidentical, cord blood), and development of nonmyeloablative conditioning regimens.

Purpose of the Study:

  • To review the current landscape and recent advancements in allogeneic stem cell transplantation.
  • To highlight changes in indications, stem cell sources, donor types, and conditioning regimens.
  • To discuss the persistent challenges and future directions in HSCT.

Related Experiment Videos

Main Methods:

  • Review of registered HSCT procedures in Italy (2003) and trends over the past 5 years.
  • Analysis of changes in stem cell sources, donor types, and conditioning regimens.
  • Evaluation of treatment outcomes, including cure rates, transplant-related mortality, and causes of morbidity (GvHD, infections).

Main Results:

  • HSCT is increasingly used for a broader range of hematologic and nonmalignant conditions, including solid tumors.
  • Peripheral blood stem cells and alternative donors are now more common than bone marrow and matched sibling donors.
  • Nonmyeloablative conditioning regimens have expanded HSCT eligibility to older patients and those with comorbidities.
  • While STI-571 has reduced HSCT for chronic myelogenous leukemia, early-stage HSCT offers >50% cure rates.
  • Transplant-related mortality remains high (20-30%), with GvHD and infections as primary concerns.
  • Promising results are emerging for haploidentical and cord blood stem cell transplantation in adults.

Conclusions:

  • Allogeneic stem cell transplantation is a vital curative therapy with evolving techniques and broader applications.
  • Despite ongoing challenges, particularly transplant-related mortality and GvHD, HSCT offers significant survival benefits for many patients.
  • Continued research into novel donor sources and conditioning strategies is crucial for further improving HSCT outcomes.